IN2014DN01883A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN01883A IN2014DN01883A IN1883DEN2014A IN2014DN01883A IN 2014DN01883 A IN2014DN01883 A IN 2014DN01883A IN 1883DEN2014 A IN1883DEN2014 A IN 1883DEN2014A IN 2014DN01883 A IN2014DN01883 A IN 2014DN01883A
- Authority
- IN
- India
- Prior art keywords
- pyridin
- chlorophenyl
- pyrazolo
- pyrrolo
- piperidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2011/065967 WO2013037411A1 (en) | 2011-09-14 | 2011-09-14 | New enzyme inhibitor compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN01883A true IN2014DN01883A (pt) | 2015-05-15 |
Family
ID=44677871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1883DEN2014 IN2014DN01883A (pt) | 2011-09-14 | 2011-09-14 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9150574B2 (pt) |
EP (1) | EP2755974A1 (pt) |
JP (1) | JP5796130B2 (pt) |
CN (1) | CN103889983B (pt) |
AU (1) | AU2011376717A1 (pt) |
BR (1) | BR112014005793A2 (pt) |
CA (1) | CA2847193A1 (pt) |
EA (1) | EA201490451A1 (pt) |
IL (1) | IL231353A0 (pt) |
IN (1) | IN2014DN01883A (pt) |
SG (1) | SG11201400277VA (pt) |
WO (1) | WO2013037411A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201304527D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
GB201304526D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
WO2014199171A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
GB201416444D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
GB201416446D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New enzyme inhibitor compounds |
GB201507031D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | New pharmaceutical salt forms |
AU2016366635A1 (en) | 2015-12-07 | 2018-06-21 | Benevolentai Cambridge Limited | VAP-1 inhibitors for treating pain |
MA47203A (fr) * | 2017-01-09 | 2019-11-13 | Ardelyx Inc | Inhibiteurs d'antiport à médiation par nhe |
JP2021535159A (ja) | 2018-08-27 | 2021-12-16 | スピノジェニックス, インコーポレイテッド | スパイン形成のためのファシン結合化合物 |
JP2022534914A (ja) | 2019-05-29 | 2022-08-04 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺微生物性誘導体 |
EP4136076A1 (en) * | 2020-04-16 | 2023-02-22 | F. Hoffmann-La Roche AG | Biphenyl derivatives |
WO2022253167A1 (en) | 2021-06-01 | 2022-12-08 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES |
WO2023193790A1 (en) * | 2022-04-08 | 2023-10-12 | Janssen Pharmaceutica Nv | Crystalline forms of an inhibitor of the menin/mll interaction |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
CA2383332C (en) | 1999-09-14 | 2006-01-10 | Aventis Pharmaceuticals Inc. | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as d4 antagonists |
AU2002214505A1 (en) * | 2000-11-09 | 2002-05-21 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives |
US6982286B2 (en) | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
ES2309206T3 (es) | 2001-10-02 | 2008-12-16 | Smithkline Beecham Corporation | Compuestos quimicos. |
US7456169B2 (en) | 2003-02-27 | 2008-11-25 | Abbott Laboratories Inc. | Heterocyclic kinase inhibitors |
WO2005014530A2 (en) | 2003-08-08 | 2005-02-17 | La Jolla Pharmaceutical Co. | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment of diseases |
BRPI0414541B8 (pt) | 2003-09-17 | 2021-05-25 | Janssen Pharmaceutica Nv | compostos heterocíclicos fundidos tendo atividade de modulação de receptor de serotonina, método de preparação de compostos intermediários |
EP1730148A4 (en) | 2004-02-03 | 2009-08-19 | Abbott Lab | USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS |
TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
AU2006239632B2 (en) | 2005-04-25 | 2012-03-15 | Merck Patent Gmbh | Novel AZA- heterocycles serving as kinase inhibitors |
ZA200800309B (en) | 2005-06-22 | 2009-10-28 | Chemocentryx Inc | Azaindazole compounds and methods of use |
US20070293548A1 (en) | 2006-03-31 | 2007-12-20 | Wang Eric Y | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases |
JP5111491B2 (ja) | 2006-04-04 | 2013-01-09 | フィブロジェン, インコーポレイテッド | ピロロ−およびピラゾロ−ピリミジン化合物、およびそれらの使用方法 |
GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
US20100099673A1 (en) | 2007-01-17 | 2010-04-22 | Bilodeau Mark T | Decahydroquinoline analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
JP2010525032A (ja) | 2007-05-02 | 2010-07-22 | ノバルティス アーゲー | ヘテロ環化合物及び殺有害生物剤としてのそれらの使用 |
GB0725103D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
DK2240482T3 (da) | 2008-01-31 | 2013-10-21 | Sanofi Sa | Cykliske azaindol-3-carboxamider, deres fremstilling og deres anvendelse som lægemidler |
WO2009108551A2 (en) | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
US8263616B2 (en) | 2008-09-16 | 2012-09-11 | Proximagen Ltd | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds |
EP2328895B1 (en) * | 2008-09-16 | 2013-03-27 | Proximagen Limited | Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO |
WO2010064020A1 (en) | 2008-12-04 | 2010-06-10 | Proximagen Ltd. | Imidazopyridine compounds |
JP2012211085A (ja) | 2009-08-12 | 2012-11-01 | Kyowa Hakko Kirin Co Ltd | ヘッジホッグシグナル阻害剤 |
GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
GB201115853D0 (en) | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
-
2011
- 2011-09-14 EP EP11761040.2A patent/EP2755974A1/en not_active Withdrawn
- 2011-09-14 EA EA201490451A patent/EA201490451A1/ru unknown
- 2011-09-14 CA CA2847193A patent/CA2847193A1/en not_active Abandoned
- 2011-09-14 US US14/344,417 patent/US9150574B2/en not_active Expired - Fee Related
- 2011-09-14 JP JP2014530103A patent/JP5796130B2/ja not_active Expired - Fee Related
- 2011-09-14 CN CN201180073402.9A patent/CN103889983B/zh not_active Expired - Fee Related
- 2011-09-14 AU AU2011376717A patent/AU2011376717A1/en not_active Abandoned
- 2011-09-14 WO PCT/EP2011/065967 patent/WO2013037411A1/en active Application Filing
- 2011-09-14 SG SG11201400277VA patent/SG11201400277VA/en unknown
- 2011-09-14 BR BR112014005793A patent/BR112014005793A2/pt not_active IP Right Cessation
- 2011-09-14 IN IN1883DEN2014 patent/IN2014DN01883A/en unknown
-
2014
- 2014-03-06 IL IL231353A patent/IL231353A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201400277VA (en) | 2014-05-29 |
CN103889983B (zh) | 2015-12-09 |
WO2013037411A1 (en) | 2013-03-21 |
JP5796130B2 (ja) | 2015-10-21 |
EA201490451A1 (ru) | 2014-12-30 |
CN103889983A (zh) | 2014-06-25 |
AU2011376717A1 (en) | 2014-03-20 |
US9150574B2 (en) | 2015-10-06 |
US20140357623A1 (en) | 2014-12-04 |
JP2015502913A (ja) | 2015-01-29 |
EP2755974A1 (en) | 2014-07-23 |
CA2847193A1 (en) | 2013-03-21 |
IL231353A0 (en) | 2014-04-30 |
BR112014005793A2 (pt) | 2017-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN01883A (pt) | ||
NZ602141A (en) | Inhibitors of semicarabazide-sensitive amine oxidase | |
RU2018115722A (ru) | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ | |
NO20161012A1 (no) | Farmasøytisk sammensetning omfattende polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-1,6-dion | |
JO3062B1 (ar) | R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري | |
MX2008008405A (es) | Metodos para tratar lupus cutaneo usando compuestos de aminoisoindolina. | |
NZ592508A (en) | Pyrazine compounds as phosphodiesterase 10 inhibitors | |
JP2017510554A5 (pt) | ||
TR201904785T4 (tr) | (S)-3-(4-((4-MORFOLINOMETİL)BENZİL)OKSİ)-1-OKSOİZOİNDOLİN-2-il)PİPERİDİN-2,6-DİON HİDROKLORİDİN BİR KATI FORMU. | |
IL190437A0 (en) | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias | |
JP2018529743A5 (pt) | ||
MX339932B (es) | Sales de 4-[2-[[5-metil-1-(2naftalenil)-1h-pirazol-3-il]oxi]etil]m orfolina. | |
JP2012508776A5 (pt) | ||
PH12013500773A1 (en) | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts | |
JP2008513405A5 (pt) | ||
AR119822A1 (es) | Triazolopirimidinas como inhibidores de a2a / a2b | |
ME01937B (me) | Upotreba 3-(4-amino-1-okso-1,3-dihidro-izoindol-2-il)-piperidin-2,6-diona za lečenje limfoma mantle ćelija | |
NZ630488A (en) | Piperidine derivatives for gpr119 agonist | |
NZ602289A (en) | Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | |
NZ607527A (en) | Fused heteroaryls and their uses | |
JP2014501269A5 (pt) | ||
NO20063921L (no) | Nye piperidiner som kjemokinmodulatorer (CCR) | |
JP2012528137A5 (pt) | ||
TR201807666T4 (tr) | Sülfonil piperidin deriveleri ve bunların prokinetisin aracılı hastalıkların tedavi edilmesine yönelik kullanımı. | |
PL2358674T3 (pl) | Sposób otrzymywania związków 4-[2-(2-fluorofenoksymetylo)fenylo]piperydyny |